01 Molecular Rapid Testing Is Replacing Conventional TB Diagnostic Methods The need for earlier and more accurate TB diagnosis is shifting testing from conventional microscopy and culture toward rapid molecular methods. WHO reported that WHO-recommended rapid diagnostic tests were used as the initial test for 54% of the 8.3 million people newly diagnosed with TB in 2024, compared with 48% in 2023. This transition shortens the time to diagnosis and supports earlier treatment decisions, strengthening demand for rapid molecular testing platforms.
02 Targeted Next-Generation Sequencing Is Expanding Drug-Resistance Detection The need to identify resistance to multiple TB medicines quickly and more comprehensively is shifting drug-resistance testing toward targeted next-generation sequencing. WHO endorsed targeted NGS in 2024 for detecting resistance to a range of first- and second-line anti-TB drugs, including through testing directly from sputum samples. **This transition expands the ability to identify resistance
01 High Global TB Burden Is Increasing Demand for Diagnostic Testing and Expansion of TB Screening Programs Is Increasing Testing Volume Drive Market The high global burden of tuberculosis creates a large and sustained need for diagnostic testing across affected populations. A greater number of suspected and exposed individuals increases demand for sputum-based, culture, molecular, and other TB diagnostic services. This demand supports wider procurement of testing kits, laboratory equipment, and related diagnostic supplies by healthcare facilities. WHO estimated that 10.7 million people developed TB globally in 2024, reinforcing the need for broad diagnostic capacity. Hospitals and public health programs use routine testing to identify cases and guide treatment.Expanded TB screening programs increase the number of people tested through hospitals, community clinics, workplaces, and targeted public-health campaigns. Broader screening activity creates additional demand for diagnostic kits, sample-collection materials, laboratory capacity, and testing services. Higher testing volumes also encourage healthcare providers to strengthen local diagnostic supply and distribution networks. For example, WHO-supported TB programs use systematic screening among high-risk populations to identify people who may otherwise remain undiagnosed. This wider screening coverage supports sustained demand for TB testing products and services
01 Limited Access to Advanced TB Diagnostic Infrastructure and High Cost of Molecular and Rapid TB Tests Restrain Market Expansion Limited access to advanced diagnostic infrastructure restricts the availability of molecular, rapid, and drug-resistance testing, particularly in rural and underserved areas. Gaps in laboratory facilities, reliable equipment, and supporting healthcare infrastructure can delay testing and limit the use of advanced diagnostic methods. These infrastructure constraints reduce testing coverage and slow the adoption of modern TB diagnostic technologies.High costs of molecular and rapid TB tests can limit their adoption among healthcare facilities with constrained diagnostic budgets. The expense of testing equipment, consumables, maintenance, and trained personnel can make advanced testing difficult to scale across resource-limited settings. These cost barriers can reduce testing volumes and restrict the broader expansion of advanced TB diagnostic solutions.
01 Growing drug-resistance detection complexity and a shortage of skilled diagnostic personnel hinders timely patient care The increasing need to identify resistance to multiple anti-TB drugs requires more sophisticated testing and interpretation capabilities. WHO reported major gaps in testing for fluoroquinolone and other drug resistance among people with rifampicin-resistant TB, limiting timely treatment selection and creating additional demands on diagnostic providers. Limited availability of trained laboratory and clinical personnel can affect sample processing, test operation, result interpretation, and quality assurance. WHO notes that adequate human resources are a prerequisite for effective uptake of modern TB diagnostic technologies, making workforce capacity an important barrier to market expansion
March 2026 The World Health Organization (WHO) recommended a new generation of near-point-of-care molecular TB diagnostic tests, together with tongue swab sampling and sputum pooling, enabling faster, lower-cost tuberculosis diagnosis and improved access in resource-limited settings.
August 2025 WHO released an updated Operational Handbook on Tuberculosis Diagnosis, providing implementation guidance for new diagnostic technologies, targeted next-generation sequencing (tNGS), and revised testing algorithms.
May 2025 WHO published updated Consolidated Guidelines on Tuberculosis Diagnosis, introducing new diagnostic technology classes and recommendations for concurrent respiratory and non-respiratory sample testing.
May–August 2025: WHO advanced global TB diagnostic innovation through updated Target Product Profiles (TPPs) for screening tests and initiatives supporting faster development and deployment of affordable, rapid diagnostics.